Autoimmune Demyelinating Disease

Por Zamvil, Scott S., Steinman, Lawrence
Publicado em 1989

Combining statins with IFNβ in MS: “Think twice, it’s not all right”

Por Zamvil, Scott S., Steinman, Lawrence
Publicado em 2011

Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?

Por Zamvil, Scott S., Slavin, Anthony J.
Publicado no Neurol Neuroimmunol Neuroinflamm (2015)

Unique invariant CD8(+) T cell population persists in MS

Por Sabatino, Joseph J., Zamvil, Scott S.
Publicado no Neurol Neuroimmunol Neuroinflamm (2015)

Your nose knows how to target brain inflammation

Por Winger, Ryan C., Zamvil, Scott S.
Publicado no Brain (2016)

Antibodies in multiple sclerosis oligoclonal bands target debris

Por Winger, Ryan C., Zamvil, Scott S.
Publicado no Proc Natl Acad Sci U S A (2016)

Statin therapy in autoimmunity: From protein prenylation to immunomodulation

Por Greenwood, John, Steinman, Lawrence, Zamvil, Scott S.
Publicado em 2006

B Cells in Multiple Sclerosis: Connecting the Dots

Por von Büdingen, H.-Christian, Bar-Or, Amit, Zamvil, Scott S.
Publicado em 2011

Laquinimod, an upcoming oral immunomodulatory agent for treatment of multiple sclerosis

Por Varrin-Doyer, Michel, Zamvil, Scott S., Schulze-Topphoff, Ulf
Publicado em 2014

K(+) Channel Alterations in the Progression of Experimental Autoimmune Encephalomyelitis

Por Jukkola, Peter, Lovett-Racke, Amy E., Zamvil, Scott S., Gu, Chen
Publicado em 2012

Accelerated Central Nervous System Autoimmunity in BAFF-Receptor-Deficient Mice

Por Kim, Susan S., Richman, David P., Zamvil, Scott S., Agius, Mark A.
Publicado em 2011

Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation

Por Li, Lihua, Zhang, Hua, Varrin-Doyer, Michel, Zamvil, Scott S., Verkman, A. S.
Publicado em 2011

Neither T-helper type 2 nor Foxp3(+) regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity

Por Weber, Martin S, Prod’homme, Thomas, Youssef, Sawsan, Dunn, Shannon E, Steinman, Lawrence, Zamvil, Scott S
Publicado em 2014

Update on the autoimmune pathology of multiple sclerosis: B cells as disease-drivers and therapeutic targets

Por von Büdingen, H.-Christian, Palanichamy, Arumugam, Lehmann-Horn, Klaus, Michel, Brady A., Zamvil, Scott S.
Publicado no Eur Neurol (2015)

Glatiramer Acetate in the Treatment of Multiple Sclerosis: Emerging Concepts Regarding its Mechanism of Action

Por Lalive, Patrice H., Neuhaus, Oliver, Benkhoucha, Mahdia, Burger, Danielle, Hohlfeld, Reinhard, Zamvil, Scott S., Weber, Martin S.
Publicado em 2011

B‐cell very late antigen‐4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity

Por Lehmann‐Horn, Klaus, Sagan, Sharon A., Bernard, Claude C.A., Sobel, Raymond A., Zamvil, Scott S.
Publicado no Ann Neurol (2015)

Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens

Por Cree, Bruce A. C., Spencer, Collin M., Varrin‐Doyer, Michel, Baranzini, Sergio E., Zamvil, Scott S.
Publicado no Ann Neurol (2016)

B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue

Por Lehmann-Horn, Klaus, Wang, Sheng-zhi, Sagan, Sharon A., Zamvil, Scott S., von Büdingen, H.-Christian
Publicado no JCI Insight (2016)

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate

Por Spencer, Collin M., Crabtree-Hartman, Elizabeth C., Lehmann-Horn, Klaus, Cree, Bruce A.C., Zamvil, Scott S.
Publicado no Neurol Neuroimmunol Neuroinflamm (2015)

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin

Por Dunn, Shannon E., Youssef, Sawsan, Goldstein, Matthew J., Prod'homme, Thomas, Weber, Martin S., Zamvil, Scott S., Steinman, Lawrence
Publicado em 2006